SpyGlass Pharma closed at $34.45 on Nov 4, unchanged — matching its highest close since Feb 6. Volume of 201.0K shares was 2.25× its 20-day average (well above normal).
Split-adjusted performance: +39.0% over one month, +37.5% over six months.
Short interest was 1.2M shares at the Oct 15 settlement, down 2.3% from the prior report (20.6% of float, 15.7 days to cover).
No reported quarters with price history yet.
Percentile among 110 companies (100 = best)
Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SGPSpyGlass Pharma | $34.45 | 0.00% | +37.5% | — | — | — | $1.15B | |
| IARTIntegra LifeSciences | $14.82 | +8.73% | +5.9% | +2.3% | 3.6% | 88.6 | $1.15B | Compare |
| IRMDiRadimed | $88.58 | +9.21% | +2.7% | +14.2% | 26.9% | 47.2 | $1.13B | Compare |
| SIBNSI-BONE | $24.95 | +4.96% | +92.1% | +15.2% | −7.3% | — | $1.12B | Compare |
| PRCTPROCEPT BioRobotics | $21.66 | +7.39% | −12.7% | +19.3% | −28.4% | — | $1.24B | Compare |
| ATECAlphatec Holdings | $8.28 | +10.84% | +18.5% | +12.6% | −2.5% | — | $1.27B | Compare |
| AORTArtivion | $26.45 | +11.56% | −23.8% | +11.3% | −10.7% | — | $1.29B | Compare |
| TNDMTandem Diabetes Care | $19.05 | +7.93% | +5.7% | +5.8% | −8.3% | — | $1.33B | Compare |
| BBNXBeta Bionics | $16.95 | +12.25% | +60.4% | +30.3% | −68.6% | — | $921.5M | Compare |
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
